Trainer John 4

Accession 0001209191-23-023686

CIK 0001538210other

View on SEC.gov Company Profile

Filed

Apr 5, 8:00 PM ET

Accepted

Apr 6, 8:41 PM ET

Size

27.0 KB

Accession

0001209191-23-023686

Insider Transaction Report

Form 4

Period: 2023-04-04

NexImmune, Inc.NEXI

Trainer John

Chief Financial Officer

Transactions

Disposition to Issuer
Stock Option (right to buy)
2023-04-04−78,100→ 0 total
Exercise: $4.22Exp: 2032-04-04→ Common Stock (78,100 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-04-04−28,987→ 0 total
Exercise: $17.00Exp: 2031-02-10→ Common Stock (28,987 underlying)
Award
Stock Option (right to buy)
2023-04-04+50,440→ 50,440 total
Exercise: $0.82Exp: 2032-04-04→ Common Stock (50,440 underlying)
Award
Stock Option (right to buy)
2023-04-04+18,720→ 18,720 total
Exercise: $1.23Exp: 2031-02-10→ Common Stock (18,720 underlying)
Award
Stock Option (right to buy)
2023-04-04+13,727→ 13,727 total
Exercise: $0.82Exp: 2030-03-04→ Common Stock (13,727 underlying)
Award
Stock Option (right to buy)
2023-04-04+89,100→ 89,100 total
Exercise: $0.41Exp: 2033-04-03→ Common Stock (89,100 underlying)
Award
Stock Option (right to buy)
2023-04-04+27,660→ 27,660 total
Exercise: $1.23Exp: 2032-04-04→ Common Stock (27,660 underlying)
Award
Stock Option (right to buy)
2023-04-04+10,267→ 10,267 total
Exercise: $0.82Exp: 2031-02-10→ Common Stock (10,267 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-04-04−102,949→ 0 total
Exercise: $5.17Exp: 2030-03-04→ Common Stock (102,949 underlying)
Award
Stock Option (right to buy)
2023-04-04+89,222→ 89,222 total
Exercise: $1.23Exp: 2030-03-04→ Common Stock (89,222 underlying)

Footnotes (4)

[F1]25% of this option shall vest and become exercisable on April 4, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Trainer's continued service to the corporation on each vesting date.
[F2]The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on April 5, 2022, of which 19,525 shares vested, and the remainder of the options will vest in equal monthly installments such that on April 5, 2026, all shares subject to the option shall be vested, subject to Mr. Trainer's continued service on each vesting date.
[F3]The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 11, 2021, of which 28,987 shares vested, and the remainder of the options will vest in equal monthly installments such that on February 11, 2025, all shares subject to the option shall be vested, subject to Mr. Trainer's continued service on each vesting date.
[F4]The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 5, 2020, of which 130,401 shares vested, and the remainder of the options will vest in equal monthly installments such that on January 8, 2024, all shares subject to the option shall be vested, subject to Mr. Trainer's continued service on each vesting date. Mr. Trainer has exercised his right to purchase an aggregate of 61,769 shares subject to the original option.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

NexImmune, Inc.

CIK 0001538210

→

Entity typeother

Related Parties

filerCIK 0001843820

Filing Metadata

Form type: 4
Filed: Apr 5, 8:00 PM ET
Accepted: Apr 6, 8:41 PM ET
Size: 27.0 KB

View on SEC.gov